With well over one million Americans living with Rheumatoid Arthritis, there has been an interest in developing antirheumatic treatments dating back to the 1930s, giving rise to the classification of “disease-modifying antirheumatic drugs” (DMARDs) in the 1970s and 1980s.
Of course, any drug or therapy will be most effective when patients adhere to the prescribed medication schedule and dosage. Nonadherence among RA patients can lead to advanced progression of the disease, increased health complications, hospital admissions, and undesirable treatment outcomes.
Factors Impacting DMARD Adherence
In the past few years, there have been several studies exploring the impacts of numerous demographic, psychological, clinical, and treatment variables on the adherence of DMARDs. Some of the findings include:
- Patients with neurotic personality traits may reject more aggressive RA therapies.
- Adherence may be positively correlated with education level and income.
- RA patients with depression are less likely to adhere to their RA medications.
- Patients participating in a structured education program are more adherent.
- Physician adherence to ACR and EULAR treat-to-target guidelines influences patient medication adherence.
If you’re conducting RA research, see our inventory of Rheumatoid Arthritis PBMC from a variety of donors.
[Related Infographic – 8 Tips for a Pain-Free Vacation with Rheumatoid Arthritis]